VAI joins oncology partnership
Craig Webb, Ph.D., director of the Program of Translational Medicine at Van Andel Institute, has joined GeneCo’s MetaMiner Oncology Partnership Program. The goal of the program is to develop a proprietary oncology pathway analysis platform built by experts in the field. Partners in the program are working in unison to develop a series of blueprint pathway maps for cancers, collect public domain experimental data and make it available for use.
“We feel that it is important to support such an initiative,” Webb said. “There is an increasing amount of information in the cancer literature but no one has brought it all together in a set of comprehensive pathway maps that can be further explored. This initiative will allow researchers to have more of a global perspective and allows newcomers to the field to get up to speed quickly.”
Webb does “amazing” work at the VAI with late-stage cancer patients, said Julie Bryant, GeneCo’s vice president of business development. “We are pleased to have him on our team. We have a lot of experience in cancer and have received millions of dollars in grants to fund our pioneering research.”
GeneCo substantially expanded the scope of its MetaMiner program this year by launching an ambitious oncology project, which is supported by a National Cancer Institute grant, and signing several Partnership agreements with leading drug companies and universities in the areas of oncology research, the central nervous system, cardiovascular diseases and stem cells.
Current members of the oncology partnership program include two large pharmaceutical companies, Harvard and Johns Hopkins, the U.S. Food and Drug Administration, the Institute of Systems Biology and Northwestern Children’s Memorial Hospital and Institute of Psychiatry.